Compare JPMorgan Ultra Short Income ETF (JPST) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Ultra Short Income ETF vs GeneDx Holdings Corp — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.49, while GeneDx Holdings Corp trades at $60.59 (market cap $1.80B). Which is the better fit depends on your goals.
| JPST | WGS | |
|---|---|---|
Sector | Leveraged / Inverse | Technology |
52-Week High | $50.78 | $167.51 |
52-Week Low | $50.40 | $34.51 |
Market Cap | — | $1.80B |
Enterprise Value | — | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPST trades at $50.49, showing minimal daily movement with a slight decline of $0.01 (-0.02%). The technical outlook is bearish based on moving averages, while oscillators signal neutrality. Recent news highlights institutional interest, with Greenwood Gearhart LLC increasing its holdings by 9.6% as of July 2026. The ETF focuses on ultra-short income, offering a cash alternative with low duration risk, as noted in Seeking Alpha analysis from April 2026.
The outlook for JPST remains stable, appealing to risk-averse investors seeking capital preservation and modest income through dividends. Key risks include interest rate sensitivity and macroeconomic shifts affecting short-term bonds. Institutional accumulation supports confidence, but the bearish technical signal warrants caution for short-term traders.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.
Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
